Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label multicenter, phase 3 trial - Argente, Jesus; Verge, Charles F; Okorie, Uzoma; Fennoy, Ilene; Kelsey, Megan M; Cokkinias, Casey; Scimia, Cecilia; Lee, Hak-Myung; Farooqi, I Sadaf (Lancet Diabetes & Endocrinology, 2025)